The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of body mass index (BMI) with progression-free survival (PFS) in patients with advanced renal cell cancer (RCC) treated with targeted therapies.
J. Dhaliwal
No relevant relationships to disclose
H. S. Gill
No relevant relationships to disclose
B. I. Chung
No relevant relationships to disclose
L. C. Harshman
Consultant or Advisory Role - Novartis
K. Rajan
No relevant relationships to disclose
S. Srinivas
Consultant or Advisory Role - Genentech; GlaxoSmithKline; Novartis; Pfizer